Bayer Shares Jump After Q1 Earnings Beat, But $2.3 Billion Legal Cash Drain Raises Questions

Bayer's stock rallies 4.5% after Q1 earnings beat and raised guidance, but massive legal payouts and rising net debt keep caution high. Agriculture division surges, pharma mixed.

Bayer’s stock rallied as much as 4.5% on Tuesday, closing at €38.58, after the German conglomerate reported first?quarter earnings that smashed analyst expectations. The company posted adjusted earnings per share of €2.71, far above the consensus estimate of €2.28, and raised its full?year guidance. Yet beneath the headline strength, a massive cash drain from legal settlements and rising net debt kept the mood cautious.

The operating engine was the agriculture division, Crop Science. Its adjusted EBITDA surged 17.9% to €3.014 billion, supported by a one?time licensing settlement with U.S. rival Corteva that contributed €448 million. The renewed approval of the herbicide Dicamba in the United States and firmer prices for crop?protection products also lent a hand. Group?wide, adjusted EBITDA rose 9% to €4.45 billion on revenue of €13.405 billion, with currency?adjusted sales up 4.1%.

Pharmaceuticals provided a more mixed picture. Patent expirations on blockbusters Xarelto and Eylea depressed the division’s adjusted EBITDA by 7.5% to €1.24 billion, but the decline was milder than feared. Newer drugs such as the cancer treatment Nubeqa helped cushion the blow. To bolster its pipeline, Bayer agreed to acquire eye?care specialist Perfuse Therapeutics for up to $2.45 billion.

The earnings beat was overshadowed by a yawning free?cash?flow deficit. Outflows of €2.32 billion in the quarter were driven largely by payments to settle PCB and glyphosate litigation, with €2 billion alone going to legal claims. Net financial debt swelled 9% to €32.5 billion. For the full year, management still expects a negative free cash flow.

Undeterred, the board upgraded its nominal targets for 2026. The new outlook calls for revenue of €44.5?46.5 billion, adjusted EBITDA of €9.4?9.9 billion, and adjusted EPS of €4.10?4.60. Analysts at JPMorgan and Barclays reaffirmed their “Overweight” ratings, with price targets of €50 and €48 respectively, providing further support to the shares.

Technically, the rally pushed the Relative Strength Index to 76.7, signaling a mildly overbought condition, while the stock built a comfortable distance above its 200?day moving average. Still, the investment case revolves around the legal overhang. A key deadline falls on June 4, when plaintiffs can opt out of the proposed $7.25 billion class?action settlement. Chief Executive Bill Anderson cautioned that “it could be a few more weeks to sort everything out,” with a final approval hearing scheduled for July.

Bayer is also awaiting a decision from the U.S. Supreme Court in the “John Durnell” case, expected in June. The company hopes a landmark ruling will clarify liability in glyphosate lawsuits and potentially reduce the risk. Until then, the market must weigh strong operational results against a legal calendar that remains in the crosshairs.